# Janssen Research & Development, LLC: Phase 3 study closed enrollment, 1135 enrolled (Bladder Cancer)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) |
| NCT ID | NCT05714202 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Bladder Cancer |
| Intervention types | drug, biological |
| Target enrollment | 1135 |
| Site countries | United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, India, Italy |
| Posted | 2023-02-06 |
| Planned start | 2023-03-23 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-25 |
| Last update posted | 2026-09-25 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 1135 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05714202). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.